FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282943850> ?p ?o ?g. }

• W4282943850 endingPage "1672" @default.
• W4282943850 startingPage "1666" @default.
• W4282943850 abstract "Background Although bacillus Calmette-Guerin (BCG) is a standard treatment for high-risk non–muscle-invasive bladder cancer (NMIBC), a high rate of adverse events with a variety of grades remains a difficulty. Objective In this randomized, prospective, multicenter study, we examined whether levofloxacin, given after each intravesical instillation of BCG, could improve its tolerance in patients with intermediate- to high-risk urothelial carcinoma of the bladder without compromising its efficacy. Design, setting, and participants Overall, 106 Japanese patients (85 men and 21 women; age: median, 69.5 yr) with primary or recurrent NMIBC were randomized after transurethral resection to induce treatment with intravesical BCG plus levofloxacin (group 1) or BCG alone (group 2). Intervention Patients who underwent intravesical instillation of BCG were randomized with or without levofloxacin administration. Outcome measurements and statistical analysis Adverse events were assessed using the National Cancer Institute-Common Toxicity Criteria version 3.0. Cumulative incidence functions and Kaplan-Meier methods were applied to estimate survival outcomes. Results and limitations There was no significant difference in baseline characteristics between the groups. The completion rate of group 1 (85.5%) was not significantly lower than that of group 2 (76.5%; p = 0.321). There was no significant difference in the completion rate of patients with pollakisuria, painful micturition, gross hematuria, fever elevation, and others between the groups. The incidence of adverse events in patients with high-grade pollakisuria (7.3% vs 25.4%, p = 0.041) and fever (0% vs 9.1%, p = 0.034) was significantly lower in group 1. The 5-yr progression-free and cancer-specific survival rates were significantly better in group 1. Conclusions Prophylactic levofloxacin administration may reduce the severity of adverse events and contribute to better outcomes from BCG intravesical therapy in patients with NMIBC. Patient summary Levofloxacin administration seems to be a safe and effective therapy for non–muscle-invasive bladder cancer patients treated with bacillus Calmette-Guerin intravesical therapy." @default.
• W4282943850 created "2022-06-16" @default.
• W4282943850 creator A5006137645 @default.
• W4282943850 creator A5011883560 @default.
• W4282943850 creator A5012066043 @default.
• W4282943850 creator A5013556794 @default.
• W4282943850 creator A5013786364 @default.
• W4282943850 creator A5023422160 @default.
• W4282943850 creator A5027892519 @default.
• W4282943850 creator A5034988483 @default.
• W4282943850 creator A5036890869 @default.
• W4282943850 creator A5041079991 @default.
• W4282943850 creator A5047951647 @default.
• W4282943850 creator A5050351809 @default.
• W4282943850 creator A5061048163 @default.
• W4282943850 creator A5061766876 @default.
• W4282943850 creator A5063835451 @default.
• W4282943850 creator A5066113574 @default.
• W4282943850 creator A5072067649 @default.
• W4282943850 creator A5073793600 @default.
• W4282943850 creator A5076873950 @default.
• W4282943850 creator A5083445257 @default.
• W4282943850 creator A5091592429 @default.
• W4282943850 date "2022-11-01" @default.
• W4282943850 modified "2023-10-07" @default.
• W4282943850 title "Effect of Levofloxacin on the Efficacy and Adverse Events in Intravesical Bacillus Calmette-Guerin Treatment for Bladder Cancer: Results of a Randomized, Prospective, Multicenter Study" @default.
• W4282943850 cites W1199133249 @default.
• W4282943850 cites W1423791052 @default.
• W4282943850 cites W1507629918 @default.
• W4282943850 cites W1586356187 @default.
• W4282943850 cites W1981503817 @default.
• W4282943850 cites W1986277645 @default.
• W4282943850 cites W2009496325 @default.
• W4282943850 cites W2030874794 @default.
• W4282943850 cites W2039069446 @default.
• W4282943850 cites W2039161970 @default.
• W4282943850 cites W2039164072 @default.
• W4282943850 cites W2086281288 @default.
• W4282943850 cites W2101773063 @default.
• W4282943850 cites W2108974158 @default.
• W4282943850 cites W2130443822 @default.
• W4282943850 cites W2134589781 @default.
• W4282943850 cites W2151575881 @default.
• W4282943850 cites W2152206210 @default.
• W4282943850 cites W2172002241 @default.
• W4282943850 cites W2567092281 @default.
• W4282943850 cites W2936086501 @default.
• W4282943850 cites W2969983122 @default.
• W4282943850 cites W2992455749 @default.
• W4282943850 cites W3013510103 @default.
• W4282943850 cites W3035939364 @default.
• W4282943850 cites W3044705077 @default.
• W4282943850 cites W3112375519 @default.
• W4282943850 cites W3120445389 @default.
• W4282943850 cites W4243650202 @default.
• W4282943850 doi "https://doi.org/10.1016/j.euf.2022.06.002" @default.
• W4282943850 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35717522" @default.
• W4282943850 hasPublicationYear "2022" @default.
• W4282943850 type Work @default.
• W4282943850 citedByCount "0" @default.
• W4282943850 crossrefType "journal-article" @default.
• W4282943850 hasAuthorship W4282943850A5006137645 @default.
• W4282943850 hasAuthorship W4282943850A5011883560 @default.
• W4282943850 hasAuthorship W4282943850A5012066043 @default.
• W4282943850 hasAuthorship W4282943850A5013556794 @default.
• W4282943850 hasAuthorship W4282943850A5013786364 @default.
• W4282943850 hasAuthorship W4282943850A5023422160 @default.
• W4282943850 hasAuthorship W4282943850A5027892519 @default.
• W4282943850 hasAuthorship W4282943850A5034988483 @default.
• W4282943850 hasAuthorship W4282943850A5036890869 @default.
• W4282943850 hasAuthorship W4282943850A5041079991 @default.
• W4282943850 hasAuthorship W4282943850A5047951647 @default.
• W4282943850 hasAuthorship W4282943850A5050351809 @default.
• W4282943850 hasAuthorship W4282943850A5061048163 @default.
• W4282943850 hasAuthorship W4282943850A5061766876 @default.
• W4282943850 hasAuthorship W4282943850A5063835451 @default.
• W4282943850 hasAuthorship W4282943850A5066113574 @default.
• W4282943850 hasAuthorship W4282943850A5072067649 @default.
• W4282943850 hasAuthorship W4282943850A5073793600 @default.
• W4282943850 hasAuthorship W4282943850A5076873950 @default.
• W4282943850 hasAuthorship W4282943850A5083445257 @default.
• W4282943850 hasAuthorship W4282943850A5091592429 @default.
• W4282943850 hasConcept C120665830 @default.
• W4282943850 hasConcept C121332964 @default.
• W4282943850 hasConcept C121608353 @default.
• W4282943850 hasConcept C126322002 @default.
• W4282943850 hasConcept C126894567 @default.
• W4282943850 hasConcept C141071460 @default.
• W4282943850 hasConcept C168563851 @default.
• W4282943850 hasConcept C188816634 @default.
• W4282943850 hasConcept C197934379 @default.
• W4282943850 hasConcept C2777661416 @default.
• W4282943850 hasConcept C2780352672 @default.
• W4282943850 hasConcept C2781276175 @default.
• W4282943850 hasConcept C501593827 @default.
• W4282943850 hasConcept C61511704 @default.
• W4282943850 hasConcept C71924100 @default.
• W4282943850 hasConcept C72563966 @default.

• next